IAPs, including XIAP and cIAP1, are overexpressed in several human cancers due to genetic alterations, abnormal activity of transcription factors controlling IAP expression and/or the absence of endogenous IAP antagonists, which contribute to the insensitivity of tumour cells towards various pharmacological treatments and unfavourable prognosis (11). The gene discussed is BIRC2; the disease is cancer.